In Brief: Anika Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics: Submits premarket approval application to FDA for its Orthovisc intra-articular injectable hyaluronic acid treatment for osteoarthritis of the knee. The PMA includes data on 226 patients treated with the product at 10 U.S. centers. Last month, Anika inked an agreement with Bristol-Myers Squibb's Zimmer subsidiary for marketing of Orthovisc in the U.S., Canada and "select Asia-Pacific markets" ("The Gray Sheet" Nov. 17, In Brief)...